Search Result

Results for "

and FGFR4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) c-Fms (1) EGFR (1) FGFR (56) HDAC (1) Isotope-Labeled Compounds (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (50) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (2) siRNAs (3)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100631

FGFR4-IN-1 1 Publications Verification	FGFR	Neurological Disease
FGFR4-IN-1 is a potent inhibiotr of *FGFR4* with IC₅₀ of 0.7 nM.

HY-115902

FGFR4-IN-7	FGFR Apoptosis	Cancer
FGFR4-IN-7 (Compound C3) is a covalent reversible *FGFR4* inhibitor with an IC₅₀ value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .

HY-147793

FGFR4-IN-12	FGFR	Cancer
FGFR4-IN-12 (Compound A34) is a potent inhibitor of *FGFR4. FGFR4-IN-12 exhibits improved FGFR4* inhibitory capability and selectivity and excellent anti-proliferative activities against FGFR4-dependent HCC cell lines. FGFR4-IN-12 has the potential for the research of cancer diseases . FGFR4-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-170690

FGFR4-IN-22	FGFR	Cancer
FGFR4-IN-22 (compound 10f) is a potent inhibitor of *FGFR4, with the IC₅₀* of 5.4 nM. FGFR4-IN-22 serve as a potential lead compound targeting FGFR4 for anti-HCC agent development .

HY-145836

FGFR4-IN-8	FGFR	Cancer
FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant *FGFR4. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4* ^V550L, FGFR4 ^V550M and FGFR4 ^C552S with IC₅₀s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC₅₀ value of 29 nM. FGFR4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model .

HY-147515

FGFR4-IN-11	FGFR	Cancer
FGFR4-IN-11 (Compound 30) is a potent, selective, covalent *FGFR4* inhibitor with an IC₅₀ of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .

HY-161610

FGFR4-IN-21	FGFR	Cancer
FGFR4-IN-21 (Compd 4c) is a *FGFR4* inhibitor with an IC₅₀ of 33 nM. FGFR4-IN-21 can be used for hepatocellular carcinoma research .

HY-163569

FGFR4-IN-20	FGFR	Cancer
FGFR4-IN-20 (comp 11) is an orally active and selective *FGFR4* inhibitor with IC₅₀s of 19 and 36 nM against Huh7 cells and FGFR4 enzyme. FGFR4-IN-20 can be used for hepatocellular carcinoma research .

HY-144759

FGFR4-IN-9	FGFR	Cancer
FGFR4-IN-9 (Compound 6O) is a selective *FGFR4* inhibitor with an IC₅₀ of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .

HY-158248

FGFR4-IN-19	FGFR	Cancer
FGFR4-IN-19 (compound 8B) is a potent covalent fibroblast growth factor receptor 4 (FGFR4) inhibitor (IC₅₀=1.2 nM). FGFR4-IN-19 achieves high efficiency and isotype selectivity by covalently targeting a rare cysteine (C552) in the *FGFR4* kinase domain. FGFR4-IN-19 can be used for hepatocellular carcinoma (HCC) research .

HY-156704

FGFR4-IN-16	FGFR	Cancer
FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of *FGFR-4* for cancer research .

HY-131704

FGFR4-IN-5	FGFR	Cancer
FGFR4-IN-5 is a potent and selective covalent *FGFR4* inhibitor with an IC₅₀ of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .

HY-155046

FGFR4-IN-14	FGFR	Cancer
FGFR4-IN-14 (Compound 27i) is a *FGFR4* inhibitor (IC₅₀: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC₅₀s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .

HY-163273

FGFR4-IN-17	FGFR	Cancer
FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a *FGFR* inhibitor with IC₅₀ values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .

HY-162283

FGFR4-IN-18	FGFR	Cancer
FGFR4-IN-18 (compound 8z) is an inhibitor of FGFR4 and can be used in cancer research .

HY-146541

FGFR4-IN-10	FGFR	Cancer
FGFR4-IN-10 (compound 5a) is a potent and selective *FGFR4* inhibitor with an IC₅₀ value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .

HY-129181

FGFR4-IN-4	FGFR	Cancer
FGFR4-IN-4 (compound 693) is a *FGFR4* inhibitor with anti-tumor activity, extracted from patent WO2018113584A1 .

HY-143881

FGFR4-IN-6	FGFR	Cancer
FGFR4-IN-6 (Compound 9ka) is a covalently reversible *FGFR4* inhibitor with an IC₅₀ value of 5.4 nM. FGFR4-IN-6 also exhibits good oral pharmacokinetic properties. FGFR4-IN-6 induces significant tumor regressions in a xenograft mouse model of Hep3B2.1-7 HCC cell line without an obvious sign of toxicity . FGFR4-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-123134

FIIN-4	FGFR	Cancer
FIIN-4 is a first-in-class, orally active and covalent *FGFR* inhibitor with IC₅₀s of 2.6 nM, 2.6 nM, 5.6 nM, 9.2 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FIIN-4 can inhibit metastatic tumor growth.

HY-RS04923

Fgfr4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) FGFR	Others
Fgfr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fgfr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fgfr4 Rat Pre-designed siRNA Set A Fgfr4 Rat Pre-designed siRNA Set A

HY-RS04921

FGFR4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) FGFR	Others
FGFR4 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FGFR4 Human Pre-designed siRNA Set A FGFR4 Human Pre-designed siRNA Set A

HY-RS04922

Fgfr4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fgfr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgfr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fgfr4 Mouse Pre-designed siRNA Set A Fgfr4 Mouse Pre-designed siRNA Set A

HY-156618

Irpagratinib ABSK011	FGFR	Cancer
Irpagratinib (ABSK011) is an orally active *FGFR4* inhibitor (IC₅₀<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model .

HY-160621

CXF-009	FGFR	Cancer
CXF-009 is a selective and covalent *FGFR4* inhibitor, with the IC₅₀ of 48 nM. CXF-009 targeting Cys477 and Cys552 of FGFR4, and can be used for the study of hepatocellular carcinoma .

HY-100492

Fisogatinib 2 Publications Verification BLU-554	FGFR	Cancer
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on *FGFR4* signalling .

HY-152104

FGFR-IN-9	FGFR	Cancer
FGFR-IN-9 (Compound 19) is a potent, reversible and orally active *FGFR* inhibitor with an IC₅₀ of 17.1, 29.6, 30.7, 46.7 and 64.3 nM against FGFR4 ^WT, FGFR3, FGFR4 ^V550L, FGFR2 and FGFR1, respectively .

HY-159691

*IONIS-FGFR4Rx* ISIS 463588	FGFR	Metabolic Disease
IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases .

HY-159691A

*IONIS-FGFR4Rx sodium* ISIS 463588 sodium	FGFR	Metabolic Disease
IONIS-FGFR4Rx (ISIS 463588) sodium is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases .

HY-161326

CXF-007	FGFR	Cancer
CXF-007 is a potent and specific *FGFR4* inhibitor with a IC₅₀ value of 7 nM. CXF-007 has antitumor activity .

HY-101568

Roblitinib 5 Publications Verification FGF-401	FGFR	Cancer
Roblitinib (FGF-401) is an orally active and highly selective *FGFR4* inhibitor with an IC₅₀ of 1.9 nM . Roblitinib has antitumor activity .

HY-18602

FIIN-2	FGFR	Cancer
FIIN-2 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-18603

FIIN-3	EGFR FGFR	Cancer
FIIN-3 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-13304

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for *FGFR1, FGFR2, FGFR3, FGFR4*, respectively.

HY-12823

BLU9931 5+ Cited Publications	FGFR	Cancer
BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity .

HY-101466

E7090	FGFR	Cancer
E7090 is an orally available, potent, and selective *FGFR* inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for *FGFR1/FGFR2/FGFR3/FGFR4*, respectively .

HY-19957

Zoligratinib 3 Publications Verification Debio 1347; CH5183284	FGFR	Cancer
Zoligratinib (Debio 1347) is an orally available and selective *FGFR* inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-13330

Fexagratinib 25+ Cited Publications AZD4547; ADSK091	FGFR	Cancer
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-13311A

Infigratinib phosphate Maximum Cited Publications 33 Publications Verification BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the *FGFR* family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-13311

Infigratinib Maximum Cited Publications 33 Publications Verification BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-13311S

Infigratinib-d3 BGJ-398-d₃; NVP-BGJ398-d₃	FGFR	Cancer
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-168286

FGFR-IN-16	FGFR	Cancer
FGFR-IN-16 (compound 7N) is a potent inhibitor of *FGFR1, FGFR2, and FGFR4, with the IC₅₀s of 8 nM, 4 nM and 3.8 nM, respectively. FGFR*-IN-16 plays an important role in cancer research ^1].

HY-109099

Pemigatinib 10+ Cited Publications INCB054828	FGFR	Cancer
Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-142921

FGFR-IN-2	FGFR	Cancer
FGFR-IN-2 (compound 1) is a potent *FGFR* inhibitor with IC₅₀s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research .

HY-13330R

Fexagratinib (Standard)	FGFR	Cancer
Fexagratinib (Standard) is the analytical standard of Fexagratinib. This product is intended for research and analytical applications. Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-P990672

U3-1784 1 Publications Verification	FGFR	Inflammation/Immunology
U3-1784 is a humanized antibody expressed in CHO that targets *FGFR4/CD334*. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-101768

PRN1371 1 Publications Verification	FGFR c-Fms	Cancer
PRN1371 is a highly selective and potent *FGFR1-4* and CSF1R inhibitor with IC₅₀s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .

HY-100019

Rogaratinib 5 Publications Verification BAY1163877	FGFR	Cancer
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively .

HY-109099R

Pemigatinib (Standard)	FGFR	Cancer
Pemigatinib (Standard) is the analytical standard of Pemigatinib. This product is intended for research and analytical applications. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-156672

S6K2-IN-1	FGFR	Cancer
S6K2-IN-1 (Compound 2) is a S6K2 inhibitor (IC₅₀: 22 nM). S6K2-IN-1 also inhibits FGFR4 (IC₅₀: 216 nM). S6K2-IN-1 has acceptable stability in mouse liver microsomes .

HY-W754878

Pemigatinib-d6 INCB054828-d₆	Isotope-Labeled Compounds FGFR	Cancer
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

Cat. No.	Product Name	Target	Research Area

HY-P990672

U3-1784 1 Publications Verification	FGFR	Inflammation/Immunology
U3-1784 is a humanized antibody expressed in CHO that targets *FGFR4/CD334*. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Chemical Structure

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-W754878

Pemigatinib-d6
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-151903S

FGFR2/3-IN-1
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks